Nordhealth ASOSL:NORDH 75 EBITDA Margin % is -14.11% as of Mar. 2026. GuruFocus rates OSL:NORDH with a GF Score™ of 75/100 and a GF Value™ of kr38.75 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 665 Healthcare Providers & Services companies, Nordhealth AS ranks worse than 78.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nordhealth AS's EBITDA for the
three
months ended in Mar. 2026 was kr-21.2 Mil. Nordhealth AS's Revenue for the
three
months ended in Mar. 2026 was kr150.4 Mil. Therefore, Nordhealth AS's EBITDA margin for the quarter that ended in Mar. 2026 was -14.11%.
Nordhealth AS (OSL:NORDH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nordhealth AS EBITDA Margin % Related Terms
Nordhealth AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nordhealth AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:NORDH vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Nordhealth AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nordhealth AS EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nordhealth AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nordhealth AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nordhealth AS (OSL:NORDH) has a EBITDA Margin % of -14.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nordhealth AS and its competitors. According to the industry distribution chart, Nordhealth AS ranks #522 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 78.5%.
Is Nordhealth AS's EBITDA Margin % too high?
Nordhealth AS's current EBITDA Margin % is -14.11%. Based on the distribution chart, Nordhealth AS ranks #522 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Nordhealth AS has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nordhealth AS's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Nordhealth AS ranks #522 out of 665 companies for EBITDA Margin %. This places Nordhealth AS in the lower half of its industry. The industry median EBITDA Margin % is 10.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nordhealth AS and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nordhealth AS's current EBITDA Margin % is -14.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nordhealth AS stock overvalued right now?
Based on GuruFocus' analysis, Nordhealth AS (OSL:NORDH) is currently considered Significantly Undervalued. The stock's GF Value™ is kr38.75, compared to a current price of kr25.60 — trading 33.9% below its estimated fair value. The current EBITDA Margin % is -14.11%. Nordhealth AS's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nordhealth AS (OSL:NORDH), the current EBITDA Margin % is -14.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nordhealth AS (OSL:NORDH) Overvalued in 2026?
Based on GuruFocus' analysis, Nordhealth AS stock appears to be undervalued.
The current stock price of kr25.60 is trading 33.9% below its estimated GF Value™ of kr38.75.
GuruFocus considers Nordhealth AS to be Significantly Undervalued.
Key valuation signals for OSL:NORDH:
EBITDA Margin %: -14.11%
GF Value™: kr38.75 vs. price of kr25.60 (33.9% below fair value)
No single metric tells the full story. See the OSL:NORDH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nordhealth AS is a cloud-based healthcare Software-as-a-Service business. Its flagship Practice Management Software (PMS), Provet for veterinary practices and Therapy Unified Platform for therapy practices, assist healthcare professionals to streamline operations and improve patient care. The majority of its revenue is generated through software subscriptions. The Group also offers additional services related to the implementation of the SaaS systems, including consultancy services, education, and data conversion. Its operating segments are: Veterinary, which generates the majority of revenue, Therapy, and Other. Geographically, Nordhealth derives maximum revenue from Norway, and the rest from Finland, the United Kingdom, Sweden, Denmark, the DACH region, and other countries.
75GF Score
Get the complete analysis for OSL:NORDH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:NORDH has been successfully added to your 
